Cullgen Announces Series Seed Financing
2018年3月1日 - 05:00PM
ビジネスワイヤ(英語)
Cullgen Inc. announced a Series Seed Financing of up to $15M by
GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery
platform based on advanced ubiquitin-mediated protein degradation
technology. In addition to GNI USA, Inc., the Company founders are
Dr. Yue Xiong, William R. Kenan Professor of Biochemistry and
Biophysics, University of North Carolina at Chapel Hill, and Dr.
Jian Jin, Professor of Pharmacological Sciences, Icahn School of
Medicine, Mount Sinai, New York. The Company is incorporated in
Delaware, USA and will concurrently initiate research operations in
the United States, Japan and China.
Cullgen’s technology focuses on selective degradation of
disease-causing proteins, including targets previously considered
undruggable. This technology can provide scientists with new means
to develop novel therapeutic approaches for various diseases. Since
1998, Dr. Xiong has been among the first to discover the catalytic
and regulatory components and the assembly mechanism of the
cullin-RING family of E3 ubiquitin ligases, enzymes that comprise
the basis of Cullgen’s technology platform. During the past several
years, Dr. Jin and Dr. Xiong have successfully developed many new
chemical entities (NCEs) against different cancer targets, which
has resulted in multiple patent applications. This new drug
discovery platform has the advantage of accelerating NCEs into
clinical development in a cost and time efficient manner to benefit
patients. Initial drug discovery programs will focus on oncology
and expand into areas such as inflammatory and autoimmune
diseases.
To-date, Cullgen has invited Dr. Lisa Carey, Dr. Stephen Frye,
and Dr. Peter Jackson, to join the company’s scientific advisory
board. They bring extensive experience and achievements in medical
oncology, drug discovery and ubiquitin research.
Cullgen's Board of Directors includes Dr. Ying Luo, President
and CEO of GNIG, Dr. Yue Xiong, Dr. Jian Jin, and Mr. Thomas
Eastling, CFO of GNIG. Other board members and corporate executives
will be appointed in the future.
About Cullgen Inc.
Cullgen is a drug discovery company leveraging
ubiquitin-mediated, small molecule-induced protein degradation
technology. The company's research programs focus on novel
treatment for cancer, inflammatory, and autoimmune diseases. For
more information, visit www.cullgen.com.
About GNI Group
GNI Group Ltd. is a multinational life-science company that
focuses on pharmaceutical and medical device businesses with
headquarters in Tokyo and subsidiaries in China and the United
States. For further information, please visit
www.gnipharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180301005559/en/
Cullgen Inc.Thomas Eastling,
+81-3-6214-3600inquiries@cullgen.com